Many people with multiple sclerosis struggle with balance and coordination, and this study uncovers a hidden reason why.

Tiziana's foralumab continues to be safe and well-tolerated, with no drug-related serious side effects after long-term use, ...

New research suggests that balance and coordination problems in multiple sclerosis may begin when key brain cells slowly run ...

There may be two distinct subtypes of multiple sclerosis, according to a new study led by scientists at University College ...

MS is currently treated with 'disease-modifying' medicines (e.g. interferon beta, glatiramer acetate, natalizumab, fingolimod, alemtuzumab, teriflunomide, and dimethyl fumarate). These medicines can ...

Brain volume loss is a key marker of degeneration in multiple sclerosis, correlated with future disability progression. Ponesimod, alemtuzumab, teriflunomide, ozanimod, and fingolimod significantly ...

This study demonstrated progressive CP enlargement over time in individuals with RRMS, averaging 1.4% a year with significant variation per participant. CP enlargement correlated with the expansion of ...

WEDNESDAY, Dec. 17, 2025 (HealthDay News) — An over-the-counter supplement called lipoic acid might help slow the loss of gray matter in the brains of people with progressive multiple sclerosis (MS), ...

A new study from Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, suggests positron emission tomography (PET) brain scans could reveal hidden inflammation ...

In contrast to traditional measures, such as an increase or worsening of lesions or overall brain atrophy, to signal progression of multiple sclerosis (MS), investigators are proposing atrophied ...

Tirisham Gyang, MD, of the Ohio State University Wexner Medical Center in Columbus, noted that the most common cognitive challenge patients with MS face is a reduction in processing speed, meaning ...